

LAST PATIENT DOSED IN ARGENICA'S PHASE 2 STROKE TRIAL

Highlights:

- *The **last patient has been dosed** in Argenica's Phase 2 clinical trial in acute ischaemic stroke patients.*
- *The Phase 2 clinical trial has dosed **a total of 92 patients** with confirmed large vessel occlusion strokes, and who underwent an endovascular thrombectomy procedure to remove the clot.*
- *The trial data will remain blinded until this last patient has had the final functional assessment performed at 90 days post stroke.*
- *Argenica anticipates **topline data from the trial to be released in Q3 calendar year 2025**, this will include data on the safety of ARG-007 and the preliminary efficacy of ARG-007 in reducing brain injury as measured by infarct volume, following stroke.*

Perth, Australia; 11 April 2025 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to announce the final patient in its Phase 2 clinical trial of ARG-007 in acute ischaemic stroke (AIS) has been dosed.

The Phase 2 clinical trial dosed a total of 92 patients with confirmed large vessel occlusion strokes, and who underwent an endovascular thrombectomy procedure to remove the clot. Of the total of 92 patients dosed, 50% received an intravenous infusion of a saline placebo and 50% received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow up functional assessment performed at 90 days post stroke. This means no one involved in dosing patients or performing follow up assessments, including principal investigators, hospital staff and Argenica staff, know which patients have been administered the saline placebo and which patients have been administered ARG-007. Following the final 90-day functional assessment, the trial database will be locked, and the data will be unblinded and analysed to confirm whether the trial has met its endpoints.

It is anticipated the topline data, reporting on the primary and secondary endpoints, will be released in Q3 calendar year 2025.

The endpoints in the trial are:

Primary – To evaluate the safety of a single dose of ARG-007 in participants with acute ischaemic stroke, including mortality rate, incidence of serious adverse events, and incidence of symptomatic intracranial haemorrhage.

Secondary – To characterize the effect of ARG-007 on reducing infarct volume in participants with acute ischaemic stroke, specifically the difference in infarct volume (brain injury volume) between ARG-007 and placebo groups as measured by magnetic resonance imaging (MRI) or non-contrast computed tomography (CT) at 48 hours post drug/placebo administration

Argenica will report to the market both the primary and secondary topline endpoint outcomes when they become available.

Dr Liz Dallimore, **Managing Director of Argenica**, stated *“We are so delighted to achieve such a significant milestone in the Company’s clinical development of ARG-007 in ischaemic stroke, and so quickly. The pace of dosing in this trial is a testament to the incredible stroke clinical research capabilities we have in Australia, our trial has outperformed similar trials conducted globally and we are so grateful to all involved for their hard work and dedication to this important Phase 2 trial. We look forward to reporting to the market the outcomes of the trial later this year”*.

Dr David Blacker, **Chair of Argenica’s Clinical Advisory Committee**, and Co-Principal Investigator on the trial, commented *“I’d first like to thank the participants - the stroke patients and their families for being a part of the study. Clinical research is vital to improving treatment of stroke. Thanks also to my colleagues around Australia who enthusiastically embraced this home-grown research. We look forward to the follow up and analysis leading to further productive collaboration.”*

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is conducting a Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.